Morgan Stanley Cuts Novo Nordisk to Underweight Over Growth Slowdown and Semaglutide Patent Cliff

Semaglutide still drives most of Novo Nordisk’s sales. Morgan Stanley and other banks warn the mid-2030s patent cliff and Eli Lilly competition look underpriced.